Development of ZYL-314

In the development of ZYL-314 we used a novel approach. First, we identified a well-known compound which is known to increase BDNF levels indirectly, and which may also bind directly to TrkB receptors. However, this active compound is highly reactive to oxygen and therefore unstable. We therefore built a way to safely encapsulate this compound in the form of a stable co-crystal salt, which allows the active compound to be rapidly absorbed after oral administration.

Our novel approach allows a known, safe and effective compound to be rapidly available to further enhance its efficacy. Importantly, the preclinical research we have completed shows that ZYL-314 has multiple neuroplasticity effects and appears to be a highly robust enhancer of BDNF/TrkB activation, even after very small oral doses. This opens the possibility of wide spread use if these preclinical results are replicated in patients.

A series of preclinical studies have demonstrated consistent findings:

BDNF Activation
Robust findings both short-term and long-term
TrkB Receptor Activation
Our studies support TrkB receptor activation and phosphorylation
Neuroplasticity
Increased brain adaptability in multiple areas

Key Findings

We have shown robust neuroplasticity findings in both the short-term and long-term, in multiple areas including:

BDNF levels in brain

BDNF / TrkB gene activation in brain

Neurogenesis (nerve growth) over long-term

Synaptogenesis (nerve connections) over long-term

Neural functioning over long-term

Neurogenesis
> 35%
Increase after 10 days
Synaptogenesis
> 150%
Increase in connections after 10 days

Independent Validation

Three independent clinical research experts in Alzheimer’s Disease, MCI, and Healthy Brain Aging have reviewed the research evidence for ZYL-314. These are some of their comments:

“I find the package of data supporting ZYL-314 as a potential treatment stimulating neuroplasticity exciting and convincing, and promising as a future treatment of neurodegenerative diseases.”

“ZYL-314’s data on its ability to modulate BDNF is robust and therefore it is a promising compound in this space.”

“Oral ZYL-314 led to marked effects on brain BDNF levels ... which suggest that the compound may be a promising intervention for neurodegenerative disorders associated with aging.”

Development Status

Program
Discovery
Preclinical
Phase 1
Phase 2
ZYL-314
Early Alzheimer’s Disease
Mild Cognitive Impairment (MCI)

The development of ZYL-314 has opened up the possibility of an extensive product platform.

For ZYL-314 itself, possibilities include different formulations, dose-ranges, and timing of administration. These can be targeted to several different indications. Additionally, we have a series of patent-protected combinations with ZYL-314 which further increase the possible range of treatment options.

The Zylorion platform offers a huge range of clinical possibilities based upon BDNF / TrkB enhancement of neuroplasticity.

Development Status

ZYL-314
Early Alzheimer’s Disease
Mild Cognitive Impairment (MCI)
Discovery
Preclinical
Phase 1
Phase 1
Phase 2
Phase 2

The development of ZYL-314 has opened up the possibility of an extensive product platform.

For ZYL-314 itself, possibilities include different formulations, dose-ranges, and timing of administration. These can be targeted to several different indications. Additionally, we have a series of patent-protected combinations with ZYL-314 which further increase the possible range of treatment options.

The Zylorion platform offers a huge range of clinical possibilities based upon BDNF / TrkB enhancement of neuroplasticity.

ZYL-314 Pipeline

Learn More

Preclinical

Phase 1

Phase 2

Preclinical

Phase 1

Phase 2

Join Our Mission

Contact Us